Taylor Lab UM
@TaylorJ_MD
Associate Professor, UM Sylvester Comprehensive Cancer Center. Physician scientist studying the role of nuclear export and kinases in hematologic cancers.
Ecstatic to announce our lab’s new paper in @ScienceMagazine in collaboration with @AbdelWahablab and @Nurix_Tx led by @Skye_Montoya, Jessie Bourcier (@jessie05866344), Mark Noviski and Hao Lu. @SylvesterCancer @MSKCancerCenter #science #biology #cancer science.org/doi/10.1126/sc…
Fantastic presentation from @samsekeres today for the @SylvesterCancer SURF program poster day! Excited about this project and the progress she made this summer!
Another #ProudPapa moment as @samsekeres presents her data on BTK degrader resistance in #CLL from the @TaylorJ_MD lab sponsored by @theNCI summer undergrad research fellowship! @SylvesterCancer @UMiamiHealth @univmiami
We have an APL patient, unfortunately uninsured/undocumented, will return to Colombia for consolidation therapy. Please let me know if any reccs for hematologists in Bogota/Cartagena! Appreciate help #leusm @MikkaelSekeres @GlopesMd
I'm honored to receive the Pap Corps Endowed Professorship in Leukemia! It's been a great 5 years @SylvesterCancer and I am looking forward to what we can achieve together with @Pap_Corps in the coming years! Thanks to Pap Corps, Susan Dinter, Sally Berenzweig & @DrSDNimer!
Recognizing the potential behind his research, @Pap_Corps appointed Dr. Justin Taylor (@TaylorJ_MD) as the newest holder of The Pap Corps Endowed Professorship in #Leukemia. 🙌 Learn more: loom.ly/O6QcnRo We're deeply thankful to our champions at The Pap Corps, whose…
Sylvester Innovates Fund Will Accelerate Early-Stage Cancer Discoveries and Inventions - InventUM (LOI deadline is August 8.) news.med.miami.edu/sylvester-inno…
Hi friends, it's #AcuteMyeloidLeukemia Thursday. Here are Top Posts of the Week! 🎉🎉🎉 1/ @TaylorJ_MD on the first patient cured by single-agent IDH1 inhibition with olutasidenib: x.com/TaylorJ_MD/sta…
Our new paper is out @Nature_NPJ Precision Oncology! rdcu.be/eujnK With @JustinWattsMD and colleagues @SylvesterCancer we report on the first patient functionally cured by single-agent IDH1 inhibition with Olutasidenib @RigelPharma for r/r #AML @NaturePortfolio 🧵
Diese IDH1-Hemmung zeigt bahnbrechende Ergebnisse bei r/r AML – ein echter Fortschritt! 🚀
Thanks @SylvesterCancer and the @umiamimedicine Stanley J. Glaser Foundation for the support! #CancerResearch #Cancer #CRCsm
Congratulations to Dr. Justin Taylor on receiving a prestigious Stanley J. Glaser Foundation Research Award to advance his work on a potential new approach to treating colorectal cancer. 🙌 The study reveals how targeting the XPO1 gene mutation with selinexor, combined with…
Thanks @oncodaily! @SylvesterCancer
Happy to Share Our Latest Paper on XPO1 R749Q Mutations Online Ahead of Print in Cancer Research - Justin Taylor @TaylorJ_MD oncodaily.com/science/315287 #Health #Oncology #OncoDaily #Medicine #Cancer @CancerWorldmag
We would like to inform you that your post has been published on OncoDaily. Thank you for sharing. oncodaily.com/science/315287
Thanks @weldeiry for your collaboration and all the other co-authors who helped with the project!
Pleased to share collaborative manuscript by Totiger et al. with @carisls and Dr. Justin Taylor at @SylvesterCancer (Nuclear Export Receptor) XPO1R749Q Mutations Co-occur with POLE Mutations in Cancer and can be Targeted to Overcome Chemoresistance pubmed.ncbi.nlm.nih.gov/40531821/
Thanks @DangH_Nguyen for being a great collaborator, co-corresponding author and all your help getting this story out!
Great to see this comes out in collaboration with @TaylorJ_MD! @UMNCancer @MPaT_PHCL_UMN
New paper @SylvesterCancer 🔥🔥🔥
Happy to share our latest paper online ahead of print in Cancer Research @CR_AACR ➡️➡️➡️ XPO1 R749Q Mutations Co-occur with POLE Mutations in Cancer and can be Targeted to Overcome Chemoresistance aacrjournals.org/cancerres/arti…